Education
About Us
Working with TipRanks
Follow Us
PINK - ETF AI Analysis
Top Page
Simplify Health Care ETF (PINK)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains over the past three months and year-to-date, indicating positive recent momentum.
Leading Health Care Holdings
Several major positions like Novo Nordisk, PureCycle Technologies, Align Tech, Amgen, and Biohaven have delivered strong year-to-date results, helping support the fund’s overall performance.
Focused Health Care Exposure
With most assets in the health care sector, the ETF gives targeted access to a key defensive area of the market that can be resilient across economic cycles.
Negative Factors
High Sector Concentration
Over 90% of the fund is invested in health care, so a downturn in this single sector could significantly hurt returns.
Top Holdings Concentration Risk
A small group of stocks makes up a large share of the portfolio, increasing the impact if any of these companies run into trouble.
Mixed Performance Among Key Stocks
Some important holdings like Regeneron, Jazz Pharmaceuticals, and Apellis Pharmaceuticals have shown weak or negative year-to-date performance, which can drag on the fund’s results.
PINK vs. SPDR S&P 500 ETF (SPY)
AUM250.79M
RegionNorth America
Expense Ratio0.51%
Beta0.64
IssuerSimplify
Inception DateOct 07, 2021
Dividend Yield0.74%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume177,751
30 Day Avg. Volume180,369
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.43Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering54
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PINK Summary
The Simplify Health Care ETF (PINK) is a fund that focuses on the health care theme rather than tracking a specific index. It invests mainly in U.S. health care companies across areas like drugs, medical devices, and health services. Well-known holdings include UnitedHealth and Eli Lilly, along with other biotech and pharmaceutical names. Someone might invest in PINK to seek long-term growth from medical innovation and the rising demand for health care as populations age. A key risk is that it is heavily concentrated in the health care sector, so its value can swing more than a broadly diversified market fund.
How much will it cost me?The Simplify Health Care ETF (PINK) has an expense ratio of 0.5%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specific sector like health care, which requires more research and expertise. It’s designed to give investors targeted exposure to innovative health care companies.
What would affect this ETF?The Simplify Health Care ETF (PINK) could benefit from advancements in biotechnology and pharmaceuticals, as well as increased demand for health care services driven by aging populations and global health awareness. However, it may face challenges from regulatory changes, pricing pressures in the pharmaceutical industry, and potential economic downturns that could impact consumer spending on health care. Its strong U.S. focus and top holdings in companies like UnitedHealth and AbbVie position it well for growth but also expose it to risks tied to U.S. health care policies.
PINK Top 10 Holdings
PINK is very much a health‑care story, with performance driven by a mix of steady giants and a few more volatile names. Align Technology is one of the fund’s rising stars, helping to pull returns higher alongside solid, steady contributors like Regeneron, Johnson & Johnson, Amgen, and Gilead. On the flip side, Eli Lilly and Novo Nordisk have been losing a bit of steam lately, while Biohaven has been a noticeable drag. The portfolio is mostly U.S.-based, with a dash of international exposure through Chugai Pharmaceutical.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Align Tech | 7.63% | $19.14M | $11.71B | -1.18% | 74 Outperform | |
| Eli Lilly & Co | 6.98% | $17.50M | $930.72B | 21.09% | 72 Outperform | |
| Novo Nordisk | 6.73% | $16.88M | $167.74B | -50.80% | 73 Outperform | |
| United Therapeutics | 6.44% | $16.14M | $23.50B | 74.50% | 79 Outperform | |
| Chugai Pharmaceutical Co | 5.31% | $13.32M | ¥15.39T | 28.50% | 74 Outperform | |
| AbbVie | 4.69% | $11.75M | $388.43B | 3.74% | 66 Neutral | |
| Johnson & Johnson | 4.68% | $11.73M | $582.04B | 48.34% | 78 Outperform | |
| Jazz Pharmaceuticals | 3.99% | $10.00M | $10.99B | 29.42% | 64 Neutral | |
| Amgen | 3.94% | $9.88M | $197.41B | 16.74% | 77 Outperform | |
| Gilead Sciences | 3.81% | $9.55M | $179.99B | 30.10% | 78 Outperform |
PINK Technical Analysis
Negative
―
Price Trends
36.37
Negative
35.91
Negative
33.06
Positive
Market Momentum
-0.59
Positive
31.61
Neutral
14.35
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PINK, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35.50, equal to the 50-day MA of 36.37, and equal to the 200-day MA of 33.06, indicating a neutral trend. The MACD of -0.59 indicates Positive momentum. The RSI at 31.61 is Neutral, neither overbought nor oversold. The STOCH value of 14.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PINK.
PINK Peer Comparison
Comparison Results
Performance Comparison
PINK
Simplify Health Care ETF
33.76
4.32
14.67%
IETC
iShares Evolved US Technology ETF
―
―
―
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
GTOP
Goldman Sachs Technology Opportunities ETF
―
―
―
RSHO
Tema American Reshoring ETF
―
―
―
IYRI
NEOS Real Estate High Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents